Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Evaluation of MAF-1217 in Patients With DED

12 juli 2019 uppdaterad av: VISUfarma SpA

Evaluation of the Performance of the Tear Substitute MAF-1217 in Patients With Evaporative DED

This is a pre-market, multicentre, double-blind, randomized, crossover, non-inferiority study comparing the efficacy of MAF-1217 and Cationorm® in adult patients with evaporative DED.

The study population will be divided in 4 different subgroups, according to the different types of evaporative DED:

  1. Group A: high evaporative levels
  2. Group B: females in menopause, whether using hormonal integration or not
  3. Group C: presence of active obstructive Meibomian gland disease
  4. Group D: glaucomatous patients

Studieöversikt

Status

Avslutad

Intervention / Behandling

Detaljerad beskrivning

Patients will be enrolled after having signed the informed consent form prior any other study procedure and after inclusion/exclusion criteria check.

Each patient will be planned to perform 6 study visits and at each visit all necessary study procedures will be performed according to the clinical investigation plan requirements (see flow-chart).

The study visits will be performed at: screening, baseline, week 2, week 6, week 8, week 12.

Patients will be enrolled at screening visit and at baseline, after the wash-out period of 1 week, then will be randomized to receive MAF-1217 or Cationorm® for the following 6 weeks.

After this time lapse, patients will be switched to the opposite therapy for 6 additional weeks.

The entire study population will be asked for a TID posology, and will be divided in 4 different subgroups, according to the different types of evaporative DED.

Certain test will be performed only in some patients:

Osmolimetry and tear sampling in 20 patients(10/site) chosen random from groups B, C and D; Ferning test only in group D; tear film collection and cytokine expression only in 20 patients form site nr. 2.

Patients will be allowed to carry on any systemic or local medications, apart lubricating eyedrops, which have to be stopped the day before baseline visit.

Studietyp

Interventionell

Inskrivning (Faktisk)

72

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Milan, Italien, 20121
        • Ospedale San Paolo, ASST Santi Paolo e Carlo
      • Milan, Italien, 20157
        • ASST Fatebenefratelli Sacco P.O.L. Sacco

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. At least 18 years old (adult patients), male and female
  2. Schirmer I test > 10 mm at 5'
  3. (Group A): high evaporative levels
  4. (Group B): females in menopause, both using hormonal integration or not
  5. (Group C): presence of active obstructive Meibomian gland disease, defined as at least one of the following:

    • Meibomian orifice plugging
    • eyelid margin foaminess
    • changes in orifice position with respect to the mucocutaneous junction
    • abnormal Meibomian gland secretions (opaque and viscous-like form that is difficult to express)
  6. (Group D): glaucomatous patients receiving one or more BAK preserved treatments for at least 2 years, showing an abnormal Ferning test (Types 3 or 4 according to Rolando)
  7. all: wishing to participate in the study and able to sign the ICF

Inclusion criteria to be checked at baseline:

  1. BUT < 7"
  2. Mild to severe DED according to OSDI chart

Exclusion Criteria:

  1. Neuropathic causes of dry eye (diabetes, long-standing contact lens wearing, previous ocular herpes infections)
  2. Coexisting corneal diseases
  3. Autoimmune diseases
  4. Past or active cicatricial conjunctivitis
  5. Past ocular surface burns
  6. Keratinization of the eyelid margin
  7. Sjogren syndrome
  8. History of corneal trauma
  9. Pregnant and lactating women
  10. Younger than 18 years old patients
  11. Use of contact lenses
  12. inability to self administer study medications
  13. (GROUPS B, D) Presence of active obstructive Meibomian gland disease
  14. (GROUP C) Presence of cicatricial Meibomian gland disease
  15. known allergic sensitivity to any of the devices ingredients or any other known allergy
  16. participation in a clinical trial during the 3 months prior to the beginning of the study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: MAF1217/Cationorm
The study population will have to self-administer the study treatment in a TID posology.
The study population will have to self-administer the study treatment in a TID posology.
Experimentell: Cationorm/MAF1217
The study population will have to self-administer the study treatment in a TID posology.
The study population will have to self-administer the study treatment in a TID posology.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Break-up time (BUT) differences
Tidsram: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Changes in break-up time (BUT) versus baseline
measured at week 2, 6, 8 and 12 weeks treatment versus baseline

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
ocular surface staining (corneal and conjunctival)
Tidsram: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Cross-over analysis for the differences versus baseline between the two groups on changes in ocular surface staining (corneal and conjunctival)
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Schirmer I test (ST) (without anesthesia)
Tidsram: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Cross-over analysis for the differences versus baseline between the two groups on changes in Schirmer I test (ST) (without anesthesia)
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
number of blinking per minute
Tidsram: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Cross-over analysis for the differences versus baseline between the two groups on changes in number of blinking per minute
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Ferning test (Group D)
Tidsram: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Cross-over analysis for the differences versus baseline between the two groups on changes in Ferning test (Group D)
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
osmolarity
Tidsram: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Cross-over analysis for the differences versus baseline between the two groups on changes in osmolarity
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
patient satisfaction (10 points VAS scale)
Tidsram: measured at week 2, 6, 8 and 12 weeks treatment versus baseline

Cross-over analysis for the differences versus baseline between the two groups on changes in patient satisfaction (10 points VAS scale).

(VAS: scale where patient has to specify level of satisfaction by indicating a position along a continuous line between two end-points (0 - 10). 0 indicates no satisfaction while 10 represents the highest level).

measured at week 2, 6, 8 and 12 weeks treatment versus baseline
OSDI
Tidsram: measured at week 2, 6, 8 and 12 weeks treatment
Changes in questionnaire scores (OSDI - Ocular Surface Disease Index). The overall Ocular Surface Disease score defined the ocular surface as normal (0-12 points) or as having mild (13-22 points), moderate (23-32 points), or severe (33-100 points) disease.
measured at week 2, 6, 8 and 12 weeks treatment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

27 november 2018

Primärt slutförande (Faktisk)

19 juni 2019

Avslutad studie (Faktisk)

19 juni 2019

Studieregistreringsdatum

Först inskickad

31 januari 2019

Först inskickad som uppfyllde QC-kriterierna

4 februari 2019

Första postat (Faktisk)

7 februari 2019

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

15 juli 2019

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 juli 2019

Senast verifierad

1 juli 2019

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

Obeslutsam

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera